76. Pituitary gonadotropin secretion hyperthyroidism
[
20 clinical trials,
32 drugs（DrugBank:
7 drugs),
2 target genes / 6 target pathways ]
Searched query = "Pituitary gonadotropin secretion hyperthyroidism", "Gonadotropin secreting pituitary adenoma", "Central precocious puberty", "Gonadotropin producing pituitary adenoma"
The queries were searched in Public_title, Scientific_title, and Condition of the data. Export date: 11/21/2019, 11/20/2019. Trials are sorted by Date_enrolment from most recent to oldest in the table.
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT03963752 | June 1, 2019 | 3 June 2019 | Clinical Trial of Rapid Progressive Central Precocious Puberty With Integrative Chinese and Western Medicine | Evidence-based Medical Research on the Treatment of Children's Rapid Progressive Central Precocious Puberty With Integrative Chinese and Western Medicine | Idiopathic Precocious Puberty | Drug: Ziyinxiehuo granules Herbs;Drug: Megestrol Acetate Tablet;Drug: Leuprorelin Acetate 3.75mg Injection | Children's Hospital of Fudan University | Not recruiting | 5 Years | 8 Years | Female | 164 | Phase 4 | ||
| 2 | NCT03695237 | October 24, 2018 | 4 November 2019 | A Study to Evaluate Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Leuprolide Acetate 45mg 6-Month Formulation in Children With Central Precocious Puberty (CPP) | A Phase 3, Multicenter, Open-Label, Two-Part Study to Evaluate the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Leuprolide Acetate 45mg 6-Month Depot Formulation in Children With Central Precocious Puberty (CPP) | Central Precocious Puberty (CPP) | Drug: Leuprolide Acetate (LA) | AbbVie | Recruiting | 2 Years | 11 Years | All | 40 | Phase 3 | United States;Puerto Rico | |
| 3 | NCT02993926 | June 24, 2017 | 18 December 2018 | A Study to Assess the Safety and Efficacy of Leuprorelin in Central Precocious Puberty (CPP) Among Chinese Participants | An Observational, Retrospective Study to Evaluate the Long Term Safety and Effectiveness of Leuprorelin in the Treatment of Central Precocious Puberty | Puberty, Precocious | Drug: Leuprorelin | Takeda | Not recruiting | N/A | N/A | All | 108 | Phase 3 | China | |
| 4 | NCT02811471 | June 2016 | 4 July 2016 | Pharmacokinetic Study of Leuprolide Acetate Injectable Suspension in the Treatment of Central Precocious Puberty | An Open-label, Single Arm, Multicenter Study on the Efficacy, Safety, and Pharmacokinetics of Leuprolide Acetate 45 mg for Injectable Suspension Controlled Release in Subjects With Central (Gonadotropin-Dependent) Precocious Puberty—Part A and B | Central Precocious Puberty | Drug: Leuprolide | Nemours Children's Clinic | Tolmar Inc. | Recruiting | 2 Years | 9 Years | Both | 5 | Phase 3 | United States |
| 5 | NCT02974270 | June 2016 | 5 December 2016 | Analysis of Body Mass Index in Central Precocious Puberty Patients Treated With Leuprolide Acetate | Analysis of Body Mass Index in Central Precocious Puberty(CPP) Patients Treated With Leuprolide Acetate | Precocious Puberty, Central | Drug: Leuprolide | Kyungpook National University | Recruiting | N/A | 9 Years | Both | 100 | Phase 4 | Korea, Republic of | |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 6 | NCT02452931 | August 31, 2015 | 15 July 2019 | Pharmacokinetic Study of Leuprolide Acetate Injectable Suspension in the Treatment of Central Precocious Puberty | An Open-label, Single Arm, Multicenter Study on the Efficacy, Safety, and Pharmacokinetics of Leuprolide Acetate 45 mg for Injectable Suspension Controlled Release in Subjects With Central (Gonadotropin-Dependent) Precocious Puberty | Precocious Puberty, Central | Drug: Leuprolide Acetate 45 mg | Tolmar Inc. | Not recruiting | 2 Years | 9 Years | All | 64 | Phase 3 | United States;Argentina;Canada;Chile;Mexico;New Zealand | |
| 7 | NCT02427958 | August 11, 2015 | 10 December 2018 | A Study to Assess the Safety and Efficacy of Leuprorelin in Central Precocious Puberty in Chinese Patients | An Open Label, Multicenter Study to Assess the Safety and Efficacy of Leuprorelin in the Treatment of Central Precocious Puberty | Puberty, Precocious | Drug: Leuprorelin | Takeda | Not recruiting | 1 Year | 9 Years | All | 300 | Phase 4 | China | |
| 8 | NCT03316482 | June 11, 2015 | 16 December 2017 | Leuprorelin Acetate DPS (Leuplin DPS) Treatment Quarterly in Patients With Central Precocious Puberty | A Multicenter, Open, Prospective Study to Evaluate the Safety and Efficacy of Leuprorelin Acetate DPS (Leuplin DPS) Treatment Quarterly in Patients With Central Precocious Puberty | Central Precocious Puberty | Drug: Leuplin DPS 11.25mg | Jin Soon Hwang | Recruiting | 4 Years | 9 Years | All | 68 | Phase 4 | Korea, Republic of | |
| 9 | EUCTR2014-004493-42-Outside-EU/EEA | 8 December 2014 | A clinical trial to determine safety and efficacy of Leuprolide Acetate 11.25mg and 30mg in children with central premature puberty | A Phase 3, Randomized, Multi-Center, Open-Label Study to Evaluate the Efficacy and Safety of Leuprolide Acetate 11.25 and 30 mg Formulations in Children with Central Precocious Puberty | Central Precocious Puberty MedDRA version: 17.1 Level: LLT Classification code 10073186 Term: Central precocious puberty System Organ Class: 100000004860 ;Therapeutic area: Diseases [C] - Hormonal diseases [C19] | Trade Name: trade name depends on the source of the product Product Name: Leuprolide acetate depot Pharmaceutical Form: Suspension for injection in pre-filled syringe INN or Proposed INN: LEUPRORELIN ACETATE CAS Number: 74381-53-6 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 11.25- Trade Name: trade name depends on the source of the product Pharmaceutical Form: Suspension for injection in pre-filled syringe INN or Proposed INN: LEUPRORELIN ACETATE CAS Number: 74381-53-6 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 30- | Abbvie previously known as Abbott | Not Available | Female: yes Male: yes | 80 | Phase 3 | United States;Puerto Rico | ||||
| 10 | EUCTR2014-004494-16-Outside-EU/EEA | 8 December 2014 | A clinical trial to determine safety and efficacy of Leuprolide Acetate 11.25mg and 30mg in children with central premature puberty | A 36 Month, Multi-Center, Open-Label Extension Study to Evaluate the Safety of Leuprolide Acetate 11.25 mg and 30 mg Formulations in Children with Central Precocious Puberty | Central Precocious Puberty MedDRA version: 17.1 Level: LLT Classification code 10073186 Term: Central precocious puberty System Organ Class: 100000004860 ;Therapeutic area: Diseases [C] - Hormonal diseases [C19] | Trade Name: trade name depends on the source of the product Pharmaceutical Form: Suspension for injection in pre-filled syringe INN or Proposed INN: LEUPRORELIN ACETATE CAS Number: 74381-53-6 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 11.25- Trade Name: trade name depends on the source of the product’ Pharmaceutical Form: Suspension for injection in pre-filled syringe INN or Proposed INN: LEUPRORELIN ACETATE CAS Number: 74381-53-6 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 30- | Abbvie previously known as Abbott | Not Available | Female: yes Male: yes | 72 | United States;Puerto Rico | |||||
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 11 | EUCTR2014-004495-36-Outside-EU/EEA | 1 December 2014 | A study of Lupron Depot Lupron Depot in treatment of central premature puberty | Study of Lupron Depot in the Treatment of Central Precocious Puberty | Central Precocious Puberty MedDRA version: 17.1 Level: LLT Classification code 10073186 Term: Central precocious puberty System Organ Class: 100000004860 ;Therapeutic area: Diseases [C] - Hormonal diseases [C19] | Trade Name: trade name depends on the source of the product Pharmaceutical Form: Suspension for injection in pre-filled syringe INN or Proposed INN: LEUPRORELIN ACETATE CAS Number: 74381-53-6 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 7.5- Trade Name: trade name depends on the source of the product Pharmaceutical Form: Suspension for injection in pre-filled syringe INN or Proposed INN: LEUPRORELIN ACETATE CAS Number: 74381-53-6 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 15.0- | Abbvie previously known as Abbott | Not Available | Female: yes Male: yes | 55 | United States | |||||
| 12 | NCT02920515 | September 2012 | 10 October 2016 | Study of Comprehensive Diagnosis and Treatment for Children Precocious Puberty | Multi-site Study of Comprehensive Treatment for Children Precocious Puberty | Central Precocious Puberty | Drug: Triptorlin or Leuprorelin;Drug: Zhibo dihuang pills;Drug: Dabu ying pills | Ruijin Hospital | Shanghai Children's Hospital;Shanghai Children's Medical Center;Xin Hua Hospital;Shanghai Children's Hospital;Shanghai Children's Medical Center;Xin Hua Hospital | Not recruiting | 2 Years | 14 Years | Female | 740 | Phase 4 | |
| 13 | NCT01467882 | April 2012 | 16 December 2017 | Efficacy, Safety, and Pharmacokinetics (PK) of Triptorelin 6-month Formulation in Patients With Central Precocious Puberty | An Open-label, Non-comparative, Multicenter Study on the Efficacy, Safety, and Pharmacokinetics of Triptorelin Pamoate (Embonate) 22.5 mg 6-month Formulation in Patients Suffering From Central (Gonadotropin-dependent) Precocious Puberty | Central Precocious Puberty | Drug: Triptorelin | Debiopharm International SA | Not recruiting | 2 Years | 9 Years | All | 44 | Phase 3 | United States;Chile;Mexico | |
| 14 | NCT01634321 | July 2011 | 19 February 2015 | The Clinical Trial to Evaluate the Efficacy and Safety of Luphere Depot Inj. 3.75mg(Leuprolide Acetate 3.75mg) in Patients With Precocious Puberty | The Phase 4 Clinical Trial to Evaluate the Efficacy and Safety of Luphere Depot Inj. 3.75mg(Leuprolide Acetate 3.75mg) in Patients With Precocious Puberty; A Single, Open, Multi-center, Prospective Study | Central Precocious Puberty | Drug: Luphere depot 3.75mg(Leuprolide acetate 3.75mg) | Daewoong Pharmaceutical Co. LTD. | Not recruiting | 4 Years | 9 Years | Both | 63 | Phase 4 | Korea, Republic of | |
| 15 | NCT01278290 | July 2010 | 19 February 2015 | Comparative Validation of the Triptorelin Test for the Diagnosis of CPP in Girls | Triptorelin Acetate Utilization for the Early Diagnosis of Central Precocious Puberty (CPP) in Girls. | Central Precocious Puberty;Sexual Precocity | Drug: Triptorelin acetate and Gonadorelin acetate;Drug: Gonadorelin acetate and Triptorelin acetate | Hospital de Niños R. Gutierrez de Buenos Aires | Not recruiting | 3 Years | 8 Years | Female | 40 | Phase 4 | Argentina | |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 16 | NCT00667446 | December 2008 | 19 October 2017 | Safety Extension Study Of Leuprolide Acetate (Lupron Depot) In The Treatment Of Central Precocious Puberty | A 36 Month, Multi-Center, Open-Label Extension Study to Evaluate the Safety of Leuprolide Acetate 11.25 mg and 30 mg Formulations in Children With Central Precocious Puberty | Precocious;Leuprolide Acetate;Luteinizing Hormone (LH);Gonadotrophin-releasing Hormone Agonist (GnRHa);Tanner Staging;Depot Formulation;Suppression of LH;Central Precocious Puberty (CPP);Gonadotrophin-releasing Hormone (GnRH);Lupron;GnRH Analog;Pediatrics Central Precocious Puberty | Drug: Leuprolide Acetate 3 Month Depot | AbbVie (prior sponsor, Abbott) | Not recruiting | N/A | N/A | All | 72 | Phase 3 | United States;Puerto Rico | |
| 17 | NCT00635817 | June 2008 | 19 October 2017 | A Study of Leuprolide 11.25 mg and 30 mg Administered Every 3 Months to Treat Central Precocious Puberty | A Phase 3, Randomized, Multi-Center, Open-Label Study to Evaluate the Efficacy and Safety of Leuprolide Acetate 11.25 and 30 mg Formulations in Children With Central Precocious Puberty | Puberty, Precocious | Drug: Leuprolide acetate 11.25 mg;Drug: Leuprolide acetate 30 mg | Abbott | Not recruiting | 2 Years | 11 Years | All | 84 | Phase 3 | United States;Puerto Rico | |
| 18 | NCT00438217 | May 2006 | 19 February 2015 | Analysis of Genetic and Environmental Parameters Influencing Growth Rate of Precocious Puberty Children | Analysis of Genetic and Environmental Parameters Influencing Growth Rate of Precocious Puberty Children | Central Precocious Puberty | Drug: Triptorelin (GnRH agonists);Drug: Leuprolide (GnRH agonists) | University of Pisa | Recruiting | 1 Year | 18 Years | Both | 100 | Phase 4 | Italy | |
| 19 | NCT00779103 | September 2004 | 29 June 2015 | Histrelin Subcutaneous Implant in Children With Central Precocious Puberty | Phase III, Open-Label Study to Evaluate Efficacy and Safety of Histrelin Subdermal Implant in Children With Central Precocious Puberty | Central Precocious Puberty | Drug: Histrelin Subcutaneous Implant | Endo Pharmaceuticals | Not recruiting | 2 Years | 10 Years | Both | 36 | Phase 3 | ||
| 20 | NCT00660010 | January 1991 | 19 October 2017 | Study of Lupron Depot In The Treatment of Central Precocious Puberty | Study of Lupron Depot In The Treatment of Central Precocious Puberty | Puberty, Precocious | Drug: Lupron (leuprolide acetate) | Abbott | Not recruiting | N/A | 10 Years | All | 55 | Phase 3 | United States |